New drug combo aims to tame rare blood cancer and prep for transplant
NCT ID NCT00492050
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests bortezomib (Velcade) and rituximab (Rituxan) as an initial treatment for Waldenstrom's macroglobulinemia, a rare blood cancer. The goal is to control the disease and collect stem cells for a possible future transplant. The study involves 46 participants and will measure how well the cancer responds after 2-3 cycles of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bortezomib (Velcade) and rituximab (Rituxan)
- What this could lead to
- If successful, this combination could help control Waldenstrom's macroglobulinemia and allow stem cell collection for future transplant if the disease worsens.
- What could go wrong
- This is a small Phase 2 trial with only 46 participants, so results may not apply to everyone. The treatment may not work for all, and side effects from the drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM'S MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.